Granules India Limited: Q2 FY25 Financial Performance Review

Executive Summary: Q2 FY25 Granules India Limited has reported a robust financial performance for the second quarter of fiscal year 2025 (ending September 30, 2024). The company demonstrated significant year-over-year (YoY) growth in both revenue and profitability, driven by strong operational execution. Key achievements include a 34.2% rise in revenue and a 37% surge in EBITDA, accompanied by an expansion in EBITDA margins. The company's balance sheet remains healthy, with a comfortable leverage ratio. Net Profit: A substantial 35% increase to ₹131 crore, compared to ₹97.2 crore in Q2 FY24. Revenue from Operations: Grew 34.2% to ₹1,297 crore from ₹966.6 crore in the corresponding prior-year period. EBITDA: Surged 37% to ₹278 crore, up from ₹203.4 crore in Q2 FY24. EBITDA Margin: Improved to 21.4%, an expansion of 40 basis points from 21.0% in Q2 FY24, indicating enhanced operational efficiency. Balance Sheet Health Net Debt: The company's net debt was reported at ₹1,024 crore. Leverage: The Net Debt to EBITDA ratio stands at a healthy 0.98x, reflecting a strong and manageable financial position. Management Commentary & Strategic Outlook Mr. Krishna Prasad Chigurupati, Chairman & Managing Director, attributed the resilient performance to "operational excellence, disciplined execution, and the strength of our governance." Key strategic highlights include: Core Business: The growth in EBITDA and PAT underscores the company's continued focus on disciplined execution and operational strength. Innovation: Management reiterated its commitment to long-term value creation through sustained investments in R&D and talent development. Peptides CDMO Platform: The company's 'Ascelis' platform (anchored by Senn Chemicals) is reportedly gaining significant visibility. Management noted "renewed customer interest and promising new discussions," signaling positive momentum in this high-value contract development and manufacturing segment.